Publication date: Feb 10, 2020
Summary of Study Protocol. This project is designed to test neurobehavioral mechanisms underlying effects of the dual orexin-1/2 receptor antagonist suvorexant on sleep efficiency and opioid abstinence, and whether these outcomes are independent of one another. This will be the first study to investigate whether suvorexant improves outpatient opioid abstinence and sleep efficiency; and whether improving sleep mediates the improved opioid abstinence outcome. 180 participants with opioid use disorder (OUD) who have just completed detoxification will complete this intent-to-treat study.
|disease||MESH||restless legs syndrome|
- Association between opioid analgesic therapy and initiation of buprenorphine management: An analysis of prescription drug monitoring program data.
- Anti-suicidal Effects of Buprenorphine in Opioid Use Disorder
- Gamified M-Health Attention Bias Modification Intervention for Individuals with Opioid Use Disorder: Protocol for a Pilot Randomised Study.
- Developing a clinical decision support for opioid use disorders: a NIDA center for the clinical trials network working group report.
- Kratom-Pharmacology, Clinical Implications, and Outlook: A Comprehensive Review.